Novo Nordisk Revenue and Competitors
Employee Data
- Novo Nordisk has 139 Employees.
- Novo Nordisk grew their employee count by 72% last year.
Novo Nordisk's People
Name | Title | Email/Phone |
---|---|---|
1 | VP and General Manager | Reveal Email/Phone |
2 | Head Finance, Procurement and Compliance | Reveal Email/Phone |
3 | Marketing Director | Reveal Email/Phone |
4 | National Sales Director | Reveal Email/Phone |
5 | Export Sales Manager | Reveal Email/Phone |
6 | Diabetes Care Specialist II at Novo Nordisk, Inc | Reveal Email/Phone |
Novo Nordisk Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $16.1M | 80 | 1% | N/A | N/A |
#2 | $32820M | 83449 | 7% | N/A | $182.4B |
#3 | $69340M | 107310 | 4% | N/A | $308.4B |
What Is Novo Nordisk?
Located in Princeton, New Jersey, headquarters for our North American business, Novo Nordisk Pharmaceuticals, Inc. has more than 1,000 employees nationwide handling sales, marketing and managed care activities, along with medical, regulatory, legal, strategic business operations and human resources responsibilities. We're the United States affiliate of Novo Nordisk A/S, Copenhagen, Denmark a world leader in diabetes care and other pharmaceutical products. And at our manufacturing facility in Clayton, North Carolina, we have more than 350 employees supplying insulin to the United States diabetes market and throughout the world.
keywords:N/AN/A
Total Funding
139
Number of Employees
N/A
Revenue (est)
72%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Novo Nordisk News
Novo Nordisk reported strong growth in fiscal 2021 with revenue and earnings per share growing in the double digits. · And due to anti-obesity...
Novo Nordisk reported strong growth in fiscal 2021 with revenue and earnings per share growing in the double digits. · And due to anti-obesity...
Novo Nordisk (NYSE:NVO), the world's leading producer of diabetes therapies that owns nearly 50% of the insulin market, is constantly trying...
Novo Nordisk (NYSE:NVO), the world's leading producer of diabetes therapies that owns nearly 50% of the insulin market, is constantly trying...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $120.2M | 583 | N/A | N/A |
#2 | $842.2M | 2228 | 4% | N/A |
#3 | $421.4M | 3117 | 4% | N/A |
#4 | N/A | 7813 | -23% | N/A |
#5 | $134600M | 64178 | 5% | N/A |